SCHEMBL20818595

SCHEMBL20818595

O=c1[nH]ncc(N2CC3(CN(Cc4ccccc4)C3)C2)c1Br

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPC5 Q9UL62 9/20 0.74
▸ ALDH1A1 P00352 1/20 0.55
▸ GAA P10253 1/20 0.41
▸ TIPARP Q7Z3E1 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ DRD4 P21917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25694641 0.85 TRPC5 (1.00) TRPC5ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL20817971 0.84 TRPC5 (0.83) TRPC5KDM4EHSD17B10
SCHEMBL20817984 0.81 TRPC5 (0.91) TRPC5ALDH1A1HSP90AA1HSP90AB1DRD2
SCHEMBL25232455 0.76 TRPC5 (0.47) TRPC5ALDH1A1TIPARP
SCHEMBL20818230 0.75 TRPC5 (0.65) TRPC5ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL20817920 0.75 TRPC5 (0.48) TRPC5ALDH1A1TIPARP
SCHEMBL4813164 0.71 ALDH1A1 (1.00) TRPC5ALDH1A1TIPARPHSP90AA1HSP90AB1
SCHEMBL27798357 0.71 SIGMAR1 (0.62) ALDH1A1GAACYP2C9CYP2C19HSD17B10
SCHEMBL20818113 0.69 TRPC5 (1.00) TRPC5ALDH1A1KMT2A
SCHEMBL14892774 0.68 DRD4 (0.59) GAATSHRMEN1CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 — — EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN TRPC5 1439/4885ALDH1A1 649/4885GAA 928/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN TRPC5 1439/4885ALDH1A1 649/4885GAA 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback